CCTV News: The reporter learned from China National Nuclear Corporation on March 21 that my country's first commercial reactor online irradiation production isotope device has achieved large-scale mass production in Qinshan Nuclear Power, breaking the long-term dependence on imports of key medical isotopes in my country.

China National Nuclear Corporation stated that Qinshan Nuclear Power has achieved mass production of cobalt 60, comprehensive localization of carbon 14 supply, and successfully released the first batch of 177 targets of glutenol, and jointly built a national nuclear technology application industry demonstration base, which is used in many fields such as medical diagnosis, industrial quality testing, and agricultural breeding. For example, carbon 14 can be used in hospital Helicobacter pylori detection and chemical drug research and development.

At present, 23 nuclear technology application projects have been signed and settled, with a total investment of 8 billion yuan. The project is expected to produce more than 20 billion yuan after the project reaches full capacity. By 2035, Qinshan Nuclear Power is expected to build a nuclear technology application industry cluster.